PAI-1在糖尿病肾病患者中的变化

目的 探讨2型糖尿病（T2DM）患者血浆纤溶酶原激活物抑制物（PAI-1）和组织型纤溶酶原激活物（t-PA）活性水平的变化及其与糖尿病肾病（DN）的关系.方法 选择133例T2DM患者,根据尿蛋白排泄率（UAER）分为无DN组67例、DN微量白蛋白尿组51例、DN临床蛋白尿组15例,正常对照组27例.测定其血浆t-PA、PAI-1的活性水平.结果 T2DM各组患者血浆PAI-1水平均显著高于正常对照组,且随着UAER的增高而递增（P＜0.05,P＜0.01）;DN患者血浆PAI-1活性与UAER、胰岛素抵抗指数（HOMA-IR）、空腹胰岛素（FINS）、胆固醇（TG）、低密度脂蛋白（LDL）、甘油三酯（TC）、体重指数（BMI）呈显著正相关;t-PA活性在各组间差异无显著性.结论 DN患者血浆PAI-1活性增高;胰岛素抵抗、高TG、高LDL、高TC血症及肥胖等因素可能与PAI-1活性增高有关.

The variation of levels of PAI-1 in patients with diabetic nepropathy

Objective To invetigate the variations of plasminogen activator inhibitor-1(PAI-1)and tissue-type plsminogen activator(t-PA)in patients with diabetic nephropathy.Methods The Plasmic levels of PAI-1 and t-PA in diabetic patients with or without diabetic nephropathy and normal controls were tested by ELISA.Results The concentrations of of PAI-1 in diabetic patients were higher than that in normal controls,and that in diabetic patients with diabetic nephropathy wer higher than that of diabetic patients without diabetic nephropathy(P<0.05,P<0.01).However,there no significant differences were observed in the levels of t-PA among these groups.Conclusion The procoagulant activity is associated with diabetic nephropathy in type-2 diabetes mellitus.